Effects of probiotics and prebiotics in ulcerative colitis

被引：11

作者：

Hijova, E. ^{[1
]}

Soltesova, A. ^{[1
]}

机构：

[1] Safarikiensis Univ, Fac Med, Inst Expt Med, Kosice, Slovakia

来源：

BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY | 2013年 / 114卷 / 09期

关键词：

ulcerative colitis; nutrition; probiotics; prebiotics; INFLAMMATORY-BOWEL-DISEASE; BIFIDOBACTERIA-FERMENTED MILK; MAINTAINING REMISSION; ESCHERICHIA-COLI; CONTROLLED-TRIAL; MESALAZINE; FLORA;

D O I：

10.4149/BLL_2013_113

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Objectives: Inflammatory bowel diseases (IBD) are caused by the failure of immunoregulatory mechanisms due to external environmental factors in genetically predisposed individuals. Probiotics and prebiotics could be used in prevention and therapy of many disorders of gastrointestinal tract including ulcerative colitis. Probiotics are living microorganisms with good tolerability and minimal risk, which confer a health benefit for the host when administered in adequate amounts. Their effect is closely related to maintaining the natural function of the intestinal flora. In this respect, they are indispensable prebiotics to protect or reduce the incidence of inflammatory lesions in diseases of the digestive tract. Conclusion: Ingestion of probiotics and prebiotics may provide some clues in developing a new class of therapeutic agents for the treatment/prevention of IBD and colitis-associated cancer (CAC) in the future (Tab. 2, Ref. 26). Full Text in PDF www.elis.sk.

引用

页码：540 / 543

页数：4

共 25 条

[1]

VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis [J].

Bibiloni, R ;

Fedorak, RN ;

Tannock, GW ;

Madsen, KL ;

Gionchetti, P ;

Campieri, M ;

De Simone, C ;

Sartor, RB .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (07) :1539-1546

[2]

Probiotics and immunity [J].

Borchers, Andrea T. ;

Selmi, Carlo ;

Meyers, Frederick J. ;

Keen, Carl L. ;

Gershwin, M. Eric .

JOURNAL OF GASTROENTEROLOGY, 2009, 44 (01) :26-46

[3]

Cierna I, 2008, GASTROENTEROL PRAX, V7, P101

[4]

Cui HH, 2004, WORLD J GASTROENTERO, V10, P1521

[5]

Diba ChS, 2010, CANC INCIDENCE SLOVA

[6]

Probiotics and the management of inflammatory bowel disease [J].

Fedorak, RN ;

Madsen, KL .

INFLAMMATORY BOWEL DISEASES, 2004, 10 (03) :286-299

[7]

Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis:: a randomised controlled pilot trial [J].

Furrie, E ;

Macfarlane, S ;

Kennedy, A ;

Cummings, JH ;

Walsh, SV ;

O'Neil, DA ;

Macfarlane, GT .

GUT, 2005, 54 (02) :242-249

[8]

Dietary modulation of the human colonic microbiota: updating the concept of prebiotics [J].

Gibson, GR ;

Probert, HM ;

Van Loo, J ;

Rastall, RA ;

Roberfroid, MB .

NUTRITION RESEARCH REVIEWS, 2004, 17 (02) :259-275

[9]

Gregus M, 2006, GASTROENTEROLOGIA, P354

[10]

In vitro screening of probiotics and synbiotics according to anti-inflammatory and anti-proliferative effects [J].

Grimoud, Julien ;

Durand, Henri ;

de Souza, Sarah ;

Monsan, Pierre ;

Ouarne, Francoise ;

Theodorou, Vassilia ;

Rogues, Christine .

INTERNATIONAL JOURNAL OF FOOD MICROBIOLOGY, 2010, 144 (01) :42-50

← 1 2 3 →